Around 1,500 people with multiple myeloma are set to benefit from the treatment, which combines belantamab mafodotin (brand name Blenrep) with bortezomib and dexamethasone.

Around 3,000 deaths and 5,500 hospital admissions in England caused by chronic heart failure could be prevented each year following our updated draft guideline on medical treatment of the disease.

Imagine a future where groundbreaking health technologies reach NHS patients in a matter of months rather than years. Where ...

Date Update 09 June 2025 The resolution start date for this topic has been delayed. The revised timeline for the evaluation will be available on the topic webpage in due course.

Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency TA1064 22 May 2025 22 May ...

People have the right to be involved in discussions and make informed decisions about their care, as described in NICE's information on making decisions about your care. Making decisions using NICE ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

This guidance has been updated and replaced by NICE guideline NG217. Back to top ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

The company has agreed a nationally available price reduction for somapacitan with the Medicines Procurement and Supply Chain. The prices agreed through the framework are commercial in confidence. The ...

NICE has today (10 th June) published final draft guidance which recommends several treatment options for around 25,000 people with moderate rheumatoid arthritis that have not responded to ...